Literature DB >> 21800003

Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis.

Claire Keogh1, Emma Wallace, Ciara Dillon, Borislav D Dimitrov, Tom Fahey.   

Abstract

The CHADS2 predicts annual risk of ischaemic stroke in non-valvular atrial fibrillation. This systematic review and meta-analysis aims to determine the predictive value of CHADS2. The literature was systematically searched from 2001 to October 2010. Data was pooled and analysed using discrimination and calibration statistical measures, using a random effects model. Eight data sets (n = 2815) were included. The diagnostic accuracy suggested a cut-point of ≥ 1 has higher sensitivity (92%) than specificity (12%) and a cut-point of ≥ 4 has higher specificity (96%) than sensitivity (33%). Lower summary estimates were observed for cut-points ≥ 2 (sensitivity 79%, specificity 42%) and ≥ 3 (specificity 77%, sensitivity 50%). There was insufficient data to analyse cut-points ≥ 5 or ≥ 6. Moderate pooled c statistic values were identified for the classic (0.63, 95% CI 0.52-0.75) and revised (0.60, 95% CI 0.43-0.72) view of stratification of the CHADS2. Calibration analysis indicated no significant difference between the predicted and observed strokes across the three risk strata for the classic or revised view. All results were associated with high heterogeneity, and conclusions should be made cautiously. In conclusion, the pooled c statistic and calibration analysis suggests minimal clinical utility of both the classic and revised view of the CHADS2 in predicting ischaemic stroke across all risk strata. Due to high heterogeneity across studies and low event rates across all risk strata, the results should be interpreted cautiously. Further validation of CHADS2 should perhaps be undertaken, given the methodological differences between many of the available validation studies and the original CHADS2 derivation study.

Entities:  

Mesh:

Year:  2011        PMID: 21800003     DOI: 10.1160/TH11-02-0061

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  18 in total

1.  Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Benjamin A Steinberg; Sunghee Kim; Laine Thomas; Gregg C Fonarow; Elaine Hylek; Jack Ansell; Alan S Go; Paul Chang; Peter Kowey; Bernard J Gersh; Kenneth W Mahaffey; Daniel E Singer; Jonathan P Piccini; Eric D Peterson
Journal:  Circulation       Date:  2014-03-29       Impact factor: 29.690

Review 2.  Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup.

Authors:  Thomas F Deering
Journal:  J Atr Fibrillation       Date:  2017-04-30

Review 3.  The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.

Authors:  Jamshed Dalal; Abhay Bhave; Abraham Oomman; Amit Vora; Anil Saxena; Dhiman Kahali; Fali Poncha; D S Gambhir; Jaydip Ray Chaudhuri; Nakul Sinha; Saumitra Ray; S S Iyengar; Suvro Banerjee; Upendra Kaul
Journal:  Indian Heart J       Date:  2015-11-24

Review 4.  Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.

Authors:  Rohan Shah; Manesh R Patel
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-09-19

Review 5.  Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy.

Authors:  Brandon W Calenda; Valentin Fuster; Jonathan L Halperin; Christopher B Granger
Journal:  Nat Rev Cardiol       Date:  2016-07-07       Impact factor: 32.419

6.  The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia.

Authors:  Yutao Guo; Gregory Y H Lip; Stavros Apostolakis
Journal:  Malays J Med Sci       Date:  2012-07

7.  The risk stratification in atrial fibrillation.

Authors:  Domenico Prisco; Caterina Cenci; Elena Silvestri; Giacomo Emmi; Tommaso Barnini; Carlo Tamburini
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

8.  Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.

Authors:  Paul L Hess; Melissa A Greiner; Gregg C Fonarow; Winslow Klaskala; Roger M Mills; Soko Setoguchi; Sana M Al-Khatib; Adrian F Hernandez; Lesley H Curtis
Journal:  Clin Cardiol       Date:  2012-10-15       Impact factor: 2.882

9.  Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey.

Authors:  Tim A Holt; Tina D Hunter; Candace Gunnarsson; Nada Khan; Paul Cload; Gregory Y H Lip
Journal:  Br J Gen Pract       Date:  2012-10       Impact factor: 5.386

Review 10.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.